Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Kualitas Luhur
Pasokan Komérsial Molnupiravir sareng Panganteur Patali sareng Kualitas Luhur
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Ngaran Kimia | Molnupiravir (EIDD-2801) |
| sinonim | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropil éster;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl) métil isobutirat |
| Nomer CAS | 2349386-89-4 |
| Nomer CAT | RF-API97 |
| Status saham | Dina Stok, Skala Produksi Nepi ka Ratusan Kilogram |
| Formula Molekul | C13H19N3O7 |
| Beurat Molekul | 329.31 |
| Kalarutan | Leyur dina DMSO |
| merek | Kimia Ruifu |
| Barang | spésifikasi |
| Penampilan | Bodas ka Pareum-Bodas Bubuk |
| Idéntifikasi IR | Spéktrum Sampel pakait sareng standar rujukan |
| Idéntifikasi HPLC | Waktos ingetan tina puncak utama solusi sampel pakait sareng solusi standar |
| Zat Patali | |
| Najis A | ≤0,15% |
| Najis B | ≤0,15% |
| Sagala Najis Unspecified | ≤0,15% |
| Total Kotoran Unspecified | ≤0,30% |
| Total Kotoran | ≤0,50% |
| Sésa pangleyur | |
| N-Heptana | ≤5000ppm |
| Étanol | ≤5000ppm |
| Isopropil asétat | ≤5000ppm |
| asetonitril | ≤410ppm |
| Métiléna Diklorida | ≤600ppm |
| aseton | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Kandungan Cai (KF) | ≤0,50% |
| Résidu on Ignition | ≤0,10% |
| Rotasi optik | -7,5° nepi ka -9,5° (C=0,5, Métanol) |
| Logam beurat | ≤10ppm |
| Purity / Métode Analisis | ≥99,5% (230nm) |
| Métode Assay / Analisis | 98.0%~102.0% (HPLC dina dasar garing) |
| Hirup Rak | 24 Bulan |
| Standar tés | Standar Perusahaan |
| Pamakéan | API, Molnupiravir (EIDD-2801) Inhibitor COVID-19 |
Bungkusan: Botol, kantong Aluminium foil, kardus drum, 25kg / Drum, atawa nurutkeun sarat customer urang.
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya, Uap jeung infestation hama.
Molnupiravir (EIDD-2801, MK-4482) mangrupikeun prodrug bioavailable oral tina analog ribonucleoside β-d-N4-hydroxycytidine (NHC; EIDD-1931) kalayan kagiatan antiviral spéktrum lega ngalawan SARS-CoV-2, MERS-CoV, SARS-CoV, sareng agén sabab COVID-19.Molnupiravir dijual kalayan nami merek Lagevrio sareng sacara umum janten emorivir.Molnupiravir parantos kabuktian ningkatkeun fungsi pulmonal, ngirangan leungitna beurat awak sareng ngirangan jumlah virus dina paru-paru.Salian kagiatan ngalawan koronavirus, Molnupiravir, dina studi laboratorium, parantos nunjukkeun kagiatan ngalawan influenza musiman sareng manuk, virus syncytial pernapasan, virus chikungunya, virus Ebola, virus encephalitis equine Venezuela, sareng virus ensefalitis equine Wétan.Molnupiravir mimitina dikembangkeun pikeun ngubaran influenza di Universitas Emory ku perusahaan inovasi ubar universitas, Drug Innovation Ventures di Emory (DRIVE), tapi dilaporkeun ditinggalkeun kusabab masalah mutagenisitas.Ieu lajeng kaala ku Ridgeback Biotherapeutics parusahaan basis Rajana, nu engké partnered kalawan Merck & Co pikeun ngembangkeun ubar salajengna.Molnupiravir disatujuan pikeun panggunaan médis di Inggris dina bulan Nopémber 2021.
